In this manner, high levels of caspase-8 are found in lenalidomide-resistant RPMI-8226 MM cells, and activation of caspase-8 weakens the anti-myeloma effect of bortezomib and lenalidomide [66] In glioblastoma, caspase-8 activates NFκB signaling, leading to enhanced proliferation, angiogenesis, and chemoresistance [65]. This evidence concerns the gene CASP8 and plasma cell myeloma.